S any conflict of interest to disclose. Data AVA I L A B I L I T Y S TAT E M E N T Anonymized data will be shared upon request by interested researchers. E T H I C A L A P P R OVA L This study was authorized by the local ethics committee Comitato Etico Azienda Ospedaliero Universitaria Cittdella Salute e della Scienza (protocol no. 314/2021, 26/07/2021). The study was performed in accordance using the World Medical Association Declaration of Helsinki. Patients and controls signed written informed consent. ORCID Francesca Palumbo Barbara Iazzolino Laura Peotta Antonio Canosa Umberto Manera Maurizio Grassano Federico Casale Rosario Vasta Cristina Moglia Andrea Calvo
ONCOLOGY LETTERS 23: 195,Simultaneous many myeloma and nonsmall cell lung carcinoma: A case report and assessment of the literatureHUANHUAN DONG1,2, JING LI3, LIN KANG4, QIANG WEI5 and YAN LI2 Department of Graduate College, Hebei North University, Zhangjiakou, Hebei 075132; two Department of Hematology, Hebei Basic Hospital, Shijiazhuang, Hebei 050051; 3 Division of Hematology, Hebei Province Hospital of Chinese Medicine, Shijiazhuang, Hebei 050013; 4Department of Pathology, Hebei General Hospital; 5 Division of Nuclear Medicine, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.HGF Protein manufacturer R.TIGIT, Cynomolgus (HEK293, His) China Received February 9, 2022; Accepted April 12, 2022 DOI: 10.3892/ol.2022.13315 Abstract. Several myeloma (MM) may be the second commonest hematologic malignancy. Synchronous presentation of MM and lung cancer is often a rare occurrence. The present study reports a case of MM combined with lung cancer and testimonials previ ously reported cases of your coexistence of nonsmall cell lung carcinoma and MM. At Hebei Common Hospital (Shijiazhuang, China), a 52yearman was diagnosed with MM difficult by lung lesion. Lung computed tomography (CT) showed a rise in lesion density after the second cycle of chemo therapy. The lesion was surgically removed and also the patient was diagnosed with nonsmall cell lung carcinoma by lung biopsy pathology. Following the fifth cycle of VDT (bortezomib, dexamethasone and thalidomide), the patient received autolo gous stem cell transplantation. Immunohistochemical staining for CD38, CD138, CD39, CD203a and TNF had been optimistic in both MM and lung cancer; CD73 was only good in lung cancer. The present study described the rare occasion of your simultaneous occurrence of MM and lung adenocarcinoma and discussed the possible link between the two tumors.PMID:36628218 CD38 could play a role in MM and lung cancer by changing the bone marrow microenvironment through adenosine. Introduction Various myeloma (MM) is characterized by an exces sive accumulation of plasma cells within the bone marrow. The diagnosis of MM requires monoclonal immunoglobulin and bone marrow examination or biopsy proof (1). CD38 and CD138 are expressed by plasma cells in myeloma (2). Studies have identified that FGFR3 and CD138 regulate autocrine and paracrine signals in MM and osteoprotegerin (OPG) has a role in myeloma bone disease through the receptor activator of nuclear element B (RANK) ligand/RANK/OPG system (35). Along with alkylating agents and corticosteroids, several new drugs have already been utilised to treat MM in current years. For example, thalidomide, bortezomib and daratumumab belong to immunomodulator proteasome inhibitors and monoclonal antibodies to CD38 are employed for MM remedy (1,six). The etiology of MM is remains to be elucidated. Nonsmall cell lung carcinoma (NSCLC) accounts for 8085 of all carcinomas with the lungs.
